← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Fast-Track Drugs And Biologics, Llc
North Potomac, MD
$34,140,780
Total funding
3
Grants
Funding over time
peak $7M · FY2009–20$10M$7.5M$5M$2.5M$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
Funding mix
By agency
NIH$34,140,780 · 3
By mechanism
N01$34,140,780 · 3
Investigators at Fast-Track Drugs And Biologics, Llc
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Not enough data
Largest grants
IGF::OT::IGF CLINICAL TRIAL$6,795,805
N01 · FY2016 · HD
IGF::OT::IGF CLINICAL TRIAL$6,484,892
N01 · FY2015 · HD
IGF::OT::IGF COORDINATING CENTER CLINICAL TRIALS"OXYTOCIN FOR ALCOHOL USE DISORDER"TASK ORDER NO. 8 - HHSN275201400001I/HHSN27500008TITLE: OXYTOCIN FOR ALCOHOL USE DISORDERPERIOD OF PERFORMANC$5,625,497
N01 · FY2017 · HD
NIAAA Clinical Trials$3,393,817
N01 · FY2014 · AA
NIAAA Medications Development Data Coordinating Center$3,108,527
N01 · FY2009 · AA
NIAAA Medications Development Data Coordinating Center$2,744,084
N01 · FY2010 · AA
IGF::OT::IGF COORDINATING CENTER CLINICAL TRIALS"OXYTOCIN FOR ALCOHOL USE DISORDER"TASK ORDER NO. 8 - HHSN275201400001I/HHSN27500008TITLE: OXYTOCIN FOR ALCOHOL USE DISORDERPERIOD OF PERFORMANC$2,580,857
N01 · FY2020 · HD
transision and completion clinical trial$2,358,423
N01 · FY2014 · AA
Pharmacokinetic Analyses Resource Center$314,510
N01 · FY2009 · DA
Program Management Task$193,160
N01 · FY2014 · AA
NIAAA Clinical Trials$182,640
N01 · FY2014 · AA
IGF::OT::IGF PROGRAM MANAGEMENT II$116,879
N01 · FY2015 · HD
IGF::OT::IGF CLINICAL TRIAL$105,150
N01 · FY2016 · HD
IGF::OT::IGF PROGRAM MANAGEMENT SERVICES FOR CLINICAL TRIALS COORDINATION$82,879
N01 · FY2016 · HD
IGF::OT::IGF Program Management Task$53,660
N01 · FY2014 · AA